Faculty Appointments
Assistant Professor of Medicine
Education
M.D., University of Miami, Miller School of Medicine, Miami, FloridaB.S., University of South Florida, Tampa, Florida
Research Description
The research program in the lab focuses on studying the role of extracellular matrix (ECM) signaling during tumor initiation and evolution. In some contexts, such as lung cancer, we have shown that cancer cells exhibit constitutive, ligand-independent activation of ECM receptors, and this signaling is required for tumor initiation. However, it is known that integrin signaling in cancer is context dependent. Thus, while some integrins may promote tumorigenesis in some cellular contexts, they may function as tumor suppressors in other cells and/or cancer types. Our current work is focused on understanding the biological factors that regulate integrin signaling in various tumor types.
Our translational and clinical work is focused on biomarker development in kidney cancer. We are leading a multi-institutional effort to collect blood samples from patients with stage IV, metastatic clear cell renal cell carcinoma who are receiving immunotherapy. We collect blood samples at multiple time points during therapy. Samples are then shipped to our lab where we extract tumor cell free DNA. We then work with collaborators at multiple institutions to identify and quantitate the tumor cell free DNA using cutting-edge Next Generation Sequencing (NGS) technologies.
Finally, we are collaborating with multiple investigators and institutions to test a novel biomarker designed to match cancer patients to the right therapy based on the biology of their tumors. This new biomarker relies on NGS-based RNA sequencing to measure the gene expression of the patient’s tumor. Based on this data, the patient is then assigned a treatment tailored to their tumor’s biology. This phase II clinical trial, termed the OPtimal Treatment by Invoking biologic Clusters in Renal Cell Carcinoma or OPTIC-RCC trial, will accrue at multiple cancer centers across the country. For more information see https://clinicaltrials.gov/ct2/show/NCT05361720.
Dr. Haake’s research has been published in multiple leading peer-reviewed journals including Cell, The New England Journal of Medicine, Cancer Cell, Cancer, Clinical Cancer Research, and others.
Our translational and clinical work is focused on biomarker development in kidney cancer. We are leading a multi-institutional effort to collect blood samples from patients with stage IV, metastatic clear cell renal cell carcinoma who are receiving immunotherapy. We collect blood samples at multiple time points during therapy. Samples are then shipped to our lab where we extract tumor cell free DNA. We then work with collaborators at multiple institutions to identify and quantitate the tumor cell free DNA using cutting-edge Next Generation Sequencing (NGS) technologies.
Finally, we are collaborating with multiple investigators and institutions to test a novel biomarker designed to match cancer patients to the right therapy based on the biology of their tumors. This new biomarker relies on NGS-based RNA sequencing to measure the gene expression of the patient’s tumor. Based on this data, the patient is then assigned a treatment tailored to their tumor’s biology. This phase II clinical trial, termed the OPtimal Treatment by Invoking biologic Clusters in Renal Cell Carcinoma or OPTIC-RCC trial, will accrue at multiple cancer centers across the country. For more information see https://clinicaltrials.gov/ct2/show/NCT05361720.
Dr. Haake’s research has been published in multiple leading peer-reviewed journals including Cell, The New England Journal of Medicine, Cancer Cell, Cancer, Clinical Cancer Research, and others.
Clinical Description
As a board-certified medical oncologist, Dr. Haake has a kidney and genitourinary cancer-focused clinic and cares for patients at both Vanderbilt University Medical Center and the Nashville VA Hospital.
Research Keywords
Kidney cancer biology, integrin signaling, tumor cell:extracellular matrix interactions, kidney cancer biomarker development, tumor cell free DNA
Publications
Haake SM, Plosa EJ, Kropski JA, Venton LA, Reddy A, Bock F, Chang BT, Luna AJ, Nabukhotna K, Xu ZQ, Prather RA, Lee S, Tanjore H, Polosukhin VV, Viquez OM, Jones A, Luo W, Wilson MH, Rathmell WK, Massion PP, Pozzi A, Blackwell TS, Zent R. Ligand-independent integrin ß1 signaling supports lung adenocarcinoma development. JCI Insight. 2022 Aug 8/8/2022; 7(15): PMID: 35763345, PII: 154098, DOI: 10.1172/jci.insight.154098, ISSN: 2379-3708.
Obradovic A, Chowdhury N, Haake SM, Ager C, Wang V, Vlahos L, Guo XV, Aggen DH, Rathmell WK, Jonasch E, Johnson JE, Roth M, Beckermann KE, Rini BI, McKiernan J, Califano A, Drake CG. Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell [print-electronic]. 2021 May 5/27/2021; 184(11): 2988-3005.e16. PMID: 34019793, PMCID: PMC8479759, PII: S0092-8674(21)00573-0, DOI: 10.1016/j.cell.2021.04.038, ISSN: 1097-4172.
Shiuan E, Reddy A, Dudzinski SO, Lim AR, Sugiura A, Hongo R, Young K, Liu XD, Smith CC, O'Neal J, Dahlman KB, McAlister R, Chen B, Ruma K, Roscoe N, Bender J, Ward J, Kim JY, Vaupel C, Bordeaux J, Ganesan S, Mayer TM, Riedlinger GM, Vincent BG, Davis NB, Haake SM, Rathmell JC, Jonasch E, Rini BI, Rathmell WK, Beckermann KE. Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. Cancers (Basel). 2021 Mar 3/23/2021; 13(6): PMID: 33806963, PMCID: PMC8004696, PII: cancers13061475, DOI: 10.3390/cancers13061475, ISSN: 2072-6694.
Wood CG, Ferguson JE, Parker JS, Moore DT, Whisenant JG, Maygarden SJ, Wallen EM, Kim WY, Milowsky MI, Beckermann KE, Davis NB, Haake SM, Karam JA, Bortone DS, Vincent BG, Powles T, Rathmell WK. Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. JCI Insight. 2020 Nov 11/19/2020; 5(22): PMID: 33208553, PMCID: PMC7710285, PII: 132852, DOI: 10.1172/jci.insight.132852, ISSN: 2379-3708.
Hapke RY, Haake SM. Hypoxia-induced epithelial to mesenchymal transition in cancer. Cancer Lett [print-electronic]. 2020 Sep 9/1/2020; 487: 10-20. PMID: 32470488, PMCID: PMC7336507, PII: S0304-3835(20)30266-4, DOI: 10.1016/j.canlet.2020.05.012, ISSN: 1872-7980.
Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, Haake SM, Isgandrova S, Martinez-Moczygemba M, Sahni N, Tannir NM, Lin SY, Rathmell WK, Jonasch E. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun. 2020 May 5/1/2020; 11(1): 2135. PMID: 32358509, PMCID: PMC7195420, PII: 10.1038/s41467-020-15959-6, DOI: 10.1038/s41467-020-15959-6, ISSN: 2041-1723.
Plosa EJ, Benjamin JT, Sucre JM, Gulleman PM, Gleaves LA, Han W, Kook S, Polosukhin VV, Haake SM, Guttentag SH, Young LR, Pozzi A, Blackwell TS, Zent R. ß1 Integrin regulates adult lung alveolar epithelial cell inflammation. JCI Insight. 2020 Jan 1/30/2020; 5(2): PMID: 31873073, PMCID: PMC7098727, PII: 129259, DOI: 10.1172/jci.insight.129259, ISSN: 2379-3708.
Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG, , Spellman PT, Rathmell WK, Linehan WM. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018 Jun 6/19/2018; 23(12): 3698. PMID: 29925010, PII: S2211-1247(18)30942-2, DOI: 10.1016/j.celrep.2018.06.032, ISSN: 2211-1247.
Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG, , Spellman PT, Rathmell WK, Linehan WM. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018 Apr 4/3/2018; 23(1): 313-326.e5. PMID: 29617669, PMCID: PMC6075733, PII: S2211-1247(18)30436-4, DOI: 10.1016/j.celrep.2018.03.075, ISSN: 2211-1247.
Siska PJ, Beckermann KE, Rathmell WK, Haake SM. Strategies to overcome therapeutic resistance in renal cell carcinoma. Urol. Oncol [print-electronic]. 2017 Mar; 35(3): 102-10. PMID: 28089416, PMCID: PMC5318278, PII: S1078-1439(16)30409-4, DOI: 10.1016/j.urolonc.2016.12.002, ISSN: 1873-2496.
Haake SM, Rathmell WK. Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making?. Cancer [print-electronic]. 2017 Jan 1/1/2017; 123(2): 200-9. PMID: 27861752, PMCID: PMC5222778, DOI: 10.1002/cncr.30314, ISSN: 1097-0142.
Haake SM, Li J, Bai Y, Kinose F, Fang B, Welsh EA, Zent R, Dhillon J, Pow-Sang JM, Chen YA, Koomen JM, Rathmell WK, Fishman M, Haura EB. Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. Clin. Cancer Res [print-electronic]. 2016 Nov 11/15/2016; 22(22): 5605-16. PMID: 27220961, PMCID: PMC5122466, PII: 1078-0432.CCR-15-1673, DOI: 10.1158/1078-0432.CCR-15-1673, ISSN: 1078-0432.
Haake SM, Weyandt JD, Rathmell WK. Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas. Mol. Cancer Res [print-electronic]. 2016 Jul; 14(7): 589-98. PMID: 27330105, PMCID: PMC4955752, PII: 1541-7786.MCR-16-0115, DOI: 10.1158/1541-7786.MCR-16-0115, ISSN: 1557-3125.
Haake SM, Brooks SA, Welsh E, Fulp WJ, Chen DT, Dhillon J, Haura E, Sexton W, Spiess PE, Pow-Sang J, Rathmell WK, Fishman M. Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. Urol. Oncol [print-electronic]. 2016 Mar; 34(3): 122.e1-7. PMID: 26546482, PMCID: PMC4761468, PII: S1078-1439(15)00480-9, DOI: 10.1016/j.urolonc.2015.09.015, ISSN: 1873-2496.
, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med [print-electronic]. 2016 Jan 1/14/2016; 374(2): 135-45. PMID: 26536169, PMCID: PMC4775252, DOI: 10.1056/NEJMoa1505917, ISSN: 1533-4406.
Smith MA, Hall R, Fisher K, Haake SM, Khalil F, Schabath MB, Vuaroqueaux V, Fiebig HH, Altiok S, Chen YA, Haura EB. Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assays. Sci Signal. 2015 Jan 1/13/2015; 8(359): ra4. PMID: 25587191, PMCID: PMC4440040, PII: 8/359/ra4, DOI: 10.1126/scisignal.2005906, ISSN: 1937-9145.
Brannon AR, Haake SM, Hacker KE, Pruthi RS, Wallen EM, Nielsen ME, Rathmell WK. Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur. Urol [print-electronic]. 2012 Feb; 61(2): 258-68. PMID: 22030119, PMCID: PMC3244546, PII: S0302-2838(11)01107-9, DOI: 10.1016/j.eururo.2011.10.007, ISSN: 1873-7560.
Van De Water TR, Abi Hachem RN, Dinh CT, Bas E, Haake SM, Hoosien G, Vivero R, Chan S, He J, Eshraghi AA, Angeli SI, Telischi FF, Balkany TJ. Conservation of hearing and protection of auditory hair cells against trauma-induced losses by local dexamethasone therapy: molecular and genetic mechanisms. Cochlear Implants Int. 2010 Jun; 11 Suppl 1: 42-55. PMID: 21756583, DOI: 10.1179/146701010X12671178390834, ISSN: 1754-7628.
Haake SM, Dinh CT, Chen S, Eshraghi AA, Van De Water TR. Dexamethasone protects auditory hair cells against TNFalpha-initiated apoptosis via activation of PI3K/Akt and NFkappaB signaling. Hear. Res [print-electronic]. 2009 Sep; 255(1-2): 22-32. PMID: 19442713, PII: S0378-5955(09)00108-7, DOI: 10.1016/j.heares.2009.05.003, ISSN: 1878-5891.
Dinh CT, Haake S, Chen S, Hoang K, Nong E, Eshraghi AA, Balkany TJ, Van De Water TR. Dexamethasone protects organ of corti explants against tumor necrosis factor-alpha-induced loss of auditory hair cells and alters the expression levels of apoptosis-related genes. Neuroscience [print-electronic]. 2008 Nov 11/19/2008; 157(2): 405-13. PMID: 18838114, PII: S0306-4522(08)01346-8, DOI: 10.1016/j.neuroscience.2008.09.012, ISSN: 0306-4522.
Dinh C, Hoang K, Haake S, Chen S, Angeli S, Nong E, Eshraghi AA, Balkany TJ, Van De Water TR. Biopolymer-released dexamethasone prevents tumor necrosis factor alpha-induced loss of auditory hair cells in vitro: implications toward the development of a drug-eluting cochlear implant electrode array. Otol. Neurotol. 2008 Oct; 29(7): 1012-9. PMID: 18818545, PII: 00129492-200810000-00024, DOI: 10.1097/MAO.0b013e3181859a1f, ISSN: 1537-4505.
Obradovic A, Chowdhury N, Haake SM, Ager C, Wang V, Vlahos L, Guo XV, Aggen DH, Rathmell WK, Jonasch E, Johnson JE, Roth M, Beckermann KE, Rini BI, McKiernan J, Califano A, Drake CG. Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell [print-electronic]. 2021 May 5/27/2021; 184(11): 2988-3005.e16. PMID: 34019793, PMCID: PMC8479759, PII: S0092-8674(21)00573-0, DOI: 10.1016/j.cell.2021.04.038, ISSN: 1097-4172.
Shiuan E, Reddy A, Dudzinski SO, Lim AR, Sugiura A, Hongo R, Young K, Liu XD, Smith CC, O'Neal J, Dahlman KB, McAlister R, Chen B, Ruma K, Roscoe N, Bender J, Ward J, Kim JY, Vaupel C, Bordeaux J, Ganesan S, Mayer TM, Riedlinger GM, Vincent BG, Davis NB, Haake SM, Rathmell JC, Jonasch E, Rini BI, Rathmell WK, Beckermann KE. Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. Cancers (Basel). 2021 Mar 3/23/2021; 13(6): PMID: 33806963, PMCID: PMC8004696, PII: cancers13061475, DOI: 10.3390/cancers13061475, ISSN: 2072-6694.
Wood CG, Ferguson JE, Parker JS, Moore DT, Whisenant JG, Maygarden SJ, Wallen EM, Kim WY, Milowsky MI, Beckermann KE, Davis NB, Haake SM, Karam JA, Bortone DS, Vincent BG, Powles T, Rathmell WK. Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. JCI Insight. 2020 Nov 11/19/2020; 5(22): PMID: 33208553, PMCID: PMC7710285, PII: 132852, DOI: 10.1172/jci.insight.132852, ISSN: 2379-3708.
Hapke RY, Haake SM. Hypoxia-induced epithelial to mesenchymal transition in cancer. Cancer Lett [print-electronic]. 2020 Sep 9/1/2020; 487: 10-20. PMID: 32470488, PMCID: PMC7336507, PII: S0304-3835(20)30266-4, DOI: 10.1016/j.canlet.2020.05.012, ISSN: 1872-7980.
Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, Haake SM, Isgandrova S, Martinez-Moczygemba M, Sahni N, Tannir NM, Lin SY, Rathmell WK, Jonasch E. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun. 2020 May 5/1/2020; 11(1): 2135. PMID: 32358509, PMCID: PMC7195420, PII: 10.1038/s41467-020-15959-6, DOI: 10.1038/s41467-020-15959-6, ISSN: 2041-1723.
Plosa EJ, Benjamin JT, Sucre JM, Gulleman PM, Gleaves LA, Han W, Kook S, Polosukhin VV, Haake SM, Guttentag SH, Young LR, Pozzi A, Blackwell TS, Zent R. ß1 Integrin regulates adult lung alveolar epithelial cell inflammation. JCI Insight. 2020 Jan 1/30/2020; 5(2): PMID: 31873073, PMCID: PMC7098727, PII: 129259, DOI: 10.1172/jci.insight.129259, ISSN: 2379-3708.
Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG, , Spellman PT, Rathmell WK, Linehan WM. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018 Jun 6/19/2018; 23(12): 3698. PMID: 29925010, PII: S2211-1247(18)30942-2, DOI: 10.1016/j.celrep.2018.06.032, ISSN: 2211-1247.
Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG, , Spellman PT, Rathmell WK, Linehan WM. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018 Apr 4/3/2018; 23(1): 313-326.e5. PMID: 29617669, PMCID: PMC6075733, PII: S2211-1247(18)30436-4, DOI: 10.1016/j.celrep.2018.03.075, ISSN: 2211-1247.
Siska PJ, Beckermann KE, Rathmell WK, Haake SM. Strategies to overcome therapeutic resistance in renal cell carcinoma. Urol. Oncol [print-electronic]. 2017 Mar; 35(3): 102-10. PMID: 28089416, PMCID: PMC5318278, PII: S1078-1439(16)30409-4, DOI: 10.1016/j.urolonc.2016.12.002, ISSN: 1873-2496.
Haake SM, Rathmell WK. Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making?. Cancer [print-electronic]. 2017 Jan 1/1/2017; 123(2): 200-9. PMID: 27861752, PMCID: PMC5222778, DOI: 10.1002/cncr.30314, ISSN: 1097-0142.
Haake SM, Li J, Bai Y, Kinose F, Fang B, Welsh EA, Zent R, Dhillon J, Pow-Sang JM, Chen YA, Koomen JM, Rathmell WK, Fishman M, Haura EB. Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. Clin. Cancer Res [print-electronic]. 2016 Nov 11/15/2016; 22(22): 5605-16. PMID: 27220961, PMCID: PMC5122466, PII: 1078-0432.CCR-15-1673, DOI: 10.1158/1078-0432.CCR-15-1673, ISSN: 1078-0432.
Haake SM, Weyandt JD, Rathmell WK. Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas. Mol. Cancer Res [print-electronic]. 2016 Jul; 14(7): 589-98. PMID: 27330105, PMCID: PMC4955752, PII: 1541-7786.MCR-16-0115, DOI: 10.1158/1541-7786.MCR-16-0115, ISSN: 1557-3125.
Haake SM, Brooks SA, Welsh E, Fulp WJ, Chen DT, Dhillon J, Haura E, Sexton W, Spiess PE, Pow-Sang J, Rathmell WK, Fishman M. Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. Urol. Oncol [print-electronic]. 2016 Mar; 34(3): 122.e1-7. PMID: 26546482, PMCID: PMC4761468, PII: S1078-1439(15)00480-9, DOI: 10.1016/j.urolonc.2015.09.015, ISSN: 1873-2496.
, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med [print-electronic]. 2016 Jan 1/14/2016; 374(2): 135-45. PMID: 26536169, PMCID: PMC4775252, DOI: 10.1056/NEJMoa1505917, ISSN: 1533-4406.
Smith MA, Hall R, Fisher K, Haake SM, Khalil F, Schabath MB, Vuaroqueaux V, Fiebig HH, Altiok S, Chen YA, Haura EB. Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assays. Sci Signal. 2015 Jan 1/13/2015; 8(359): ra4. PMID: 25587191, PMCID: PMC4440040, PII: 8/359/ra4, DOI: 10.1126/scisignal.2005906, ISSN: 1937-9145.
Brannon AR, Haake SM, Hacker KE, Pruthi RS, Wallen EM, Nielsen ME, Rathmell WK. Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur. Urol [print-electronic]. 2012 Feb; 61(2): 258-68. PMID: 22030119, PMCID: PMC3244546, PII: S0302-2838(11)01107-9, DOI: 10.1016/j.eururo.2011.10.007, ISSN: 1873-7560.
Van De Water TR, Abi Hachem RN, Dinh CT, Bas E, Haake SM, Hoosien G, Vivero R, Chan S, He J, Eshraghi AA, Angeli SI, Telischi FF, Balkany TJ. Conservation of hearing and protection of auditory hair cells against trauma-induced losses by local dexamethasone therapy: molecular and genetic mechanisms. Cochlear Implants Int. 2010 Jun; 11 Suppl 1: 42-55. PMID: 21756583, DOI: 10.1179/146701010X12671178390834, ISSN: 1754-7628.
Haake SM, Dinh CT, Chen S, Eshraghi AA, Van De Water TR. Dexamethasone protects auditory hair cells against TNFalpha-initiated apoptosis via activation of PI3K/Akt and NFkappaB signaling. Hear. Res [print-electronic]. 2009 Sep; 255(1-2): 22-32. PMID: 19442713, PII: S0378-5955(09)00108-7, DOI: 10.1016/j.heares.2009.05.003, ISSN: 1878-5891.
Dinh CT, Haake S, Chen S, Hoang K, Nong E, Eshraghi AA, Balkany TJ, Van De Water TR. Dexamethasone protects organ of corti explants against tumor necrosis factor-alpha-induced loss of auditory hair cells and alters the expression levels of apoptosis-related genes. Neuroscience [print-electronic]. 2008 Nov 11/19/2008; 157(2): 405-13. PMID: 18838114, PII: S0306-4522(08)01346-8, DOI: 10.1016/j.neuroscience.2008.09.012, ISSN: 0306-4522.
Dinh C, Hoang K, Haake S, Chen S, Angeli S, Nong E, Eshraghi AA, Balkany TJ, Van De Water TR. Biopolymer-released dexamethasone prevents tumor necrosis factor alpha-induced loss of auditory hair cells in vitro: implications toward the development of a drug-eluting cochlear implant electrode array. Otol. Neurotol. 2008 Oct; 29(7): 1012-9. PMID: 18818545, PII: 00129492-200810000-00024, DOI: 10.1097/MAO.0b013e3181859a1f, ISSN: 1537-4505.